332 related articles for article (PubMed ID: 22448011)
1. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
[TBL] [Abstract][Full Text] [Related]
2. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.
Giles BM; Ross TM
Vaccine; 2011 Apr; 29(16):3043-54. PubMed ID: 21320540
[TBL] [Abstract][Full Text] [Related]
3. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.
Giles BM; Bissel SJ; Dealmeida DR; Wiley CA; Ross TM
Clin Vaccine Immunol; 2012 Feb; 19(2):128-39. PubMed ID: 22190399
[TBL] [Abstract][Full Text] [Related]
4. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
Crevar CJ; Carter DM; Lee KY; Ross TM
Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
[TBL] [Abstract][Full Text] [Related]
5. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.
Carter DM; Darby CA; Lefoley BC; Crevar CJ; Alefantis T; Oomen R; Anderson SF; Strugnell T; Cortés-Garcia G; Vogel TU; Parrington M; Kleanthous H; Ross TM
J Virol; 2016 May; 90(9):4720-4734. PubMed ID: 26912624
[TBL] [Abstract][Full Text] [Related]
6. A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.
Ross TM; DiNapoli J; Giel-Moloney M; Bloom CE; Bertran K; Balzli C; Strugnell T; Sá E Silva M; Mebatsion T; Bublot M; Swayne DE; Kleanthous H
Vaccine; 2019 Apr; 37(17):2369-2376. PubMed ID: 30905528
[TBL] [Abstract][Full Text] [Related]
7. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
8. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
[TBL] [Abstract][Full Text] [Related]
9. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
10. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
Crevar CJ; Ross TM
Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
[TBL] [Abstract][Full Text] [Related]
11. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
13. Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.
Reneer ZB; Jamieson PJ; Skarlupka AL; Huang Y; Ross TM
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115871
[TBL] [Abstract][Full Text] [Related]
14. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
15. Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses.
Reneer ZB; Skarlupka AL; Jamieson PJ; Ross TM
mSphere; 2021 Mar; 6(2):. PubMed ID: 33692193
[TBL] [Abstract][Full Text] [Related]
16. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
17. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
18. Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.
Skarlupka AL; Owino SO; Suzuki-Williams LP; Crevar CJ; Carter DM; Ross TM
Hum Vaccin Immunother; 2019; 15(9):2013-2029. PubMed ID: 31448974
[TBL] [Abstract][Full Text] [Related]
19. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
20. Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses.
Nuñez IA; Ross TM
Vaccine; 2020 Jan; 38(4):830-839. PubMed ID: 31733946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
